Holen Sie sich die Stockscreener-App
0.4843
1.16%
-0.0057
Handel nachbörslich:
.49
0.0057
+1.18%
Atyr Pharma Inc Aktie (ATYR) Neueste Nachrichten
Why Is aTyr Stock Falling Today? - MSN
ATyr Pharma revamps efzofitimod path with new phase III sarcoidosis trial - MSN
aTyr Pharma stock (US53227K1025): clinical pipeline update keeps biotech in focus - AD HOC NEWS
Freedom Capital Markets Initiates ATyr Pharma(ATYR.US) With Buy Rating, Announces Target Price $3.5 - Moomoo
ATYR Upgraded by Freedom Broker -- Price Target Raised to $3.50 - GuruFocus
ATyr Pharma Raised to Buy From Hold by Freedom Broker - Moomoo
ATyr Pharma Price Target Raised to $3.50/Share From $1.00 by Freedom Broker - Moomoo
aTyr Pharma upgraded to Buy from Hold at Freedom Broker - TipRanks
Freedom Broker upgrades ATYR Pharma (ATYR) - MSN
Atyr plans new global clinical trial of efzofitimod in pulmonary sarcoidosis - Sarcoidosis News
aTyr Pharma(ATYR) Stock Options Chain | Quotes & News - Moomoo
aTyr Pharma stock (US0021202025): fresh quarterly loss keeps biotech in focus - AD HOC NEWS
Number of shareholders of aTyr Pharma, Inc. – NASDAQ:ATYR - TradingView
Number of shareholders of aTyr Pharma, Inc. – LS:A2PM86 - TradingView
aTyr Pharma Inc stock (US53227K1025): biotech under pressure as short interest jumps and earnings su - AD HOC NEWS
JonesTrading Maintains ATyr Pharma(ATYR.US) With Hold Rating - Moomoo
[10-Q] aTYR PHARMA INC Quarterly Earnings Report - Stock Titan
aTyr: Advancing Efzofitimod for Pulmonary Sarcoidosis - GuruFocus
aTyr Pharma Inc options imply 30.5% move in share price post-earnings - TipRanks
aTyr Pharma Reports Q1 2026 Results, Advances Efzofitimod Phase 3 for Pulmonary Sarcoidosis After FDA Meeting - Minichart
ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
aTyr Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update - The Manila Times
Atyr Pharma: Q1 Earnings Snapshot - marketscreener.com
aTyr Pharma (NASDAQ: ATYR) details Q1 2026 loss and Phase 3 plan - Stock Titan
aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III ResultsSlideshow (NASDAQ:ATYR) 2026-05-14 - Seeking Alpha
ATYR SEC FilingsAtyr Pharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
aTyr Pharma stock (US53227K1025): Biotech innovator in pulmonary disease therapies - AD HOC NEWS
[Form 4] aTYR PHARMA INC Insider Trading Activity - Stock Titan
Director at aTYR Pharma (ATYR) receives 50,000-share stock option grant - Stock Titan
Director Jane Gross (ATYR) awarded 50,000 aTyr Pharma stock options at $0.95 - Stock Titan
aTyr Pharma to Participate in Upcoming Investor Conferences - The Manila Times
Director at aTYR Pharma (ATYR) receives 50,000 stock options grant - Stock Titan
aTYR Pharma (ATYR) director receives 50,000-share stock option grant - Stock Titan
aTYR Pharma (ATYR) awards director Paul Schimmel 50,000 stock options at $0.95 - Stock Titan
ATyr Pharma to Participate in Upcoming Investor Conferences - marketscreener.com
Biotech developing lung disease drug plans Jefferies fireside chat - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
aTyr Pharma stock tumbles on new Phase 3 trial plans By Investing.com - Investing.com South Africa
Wells Fargo Maintains ATyr Pharma(ATYR.US) With Hold Rating, Maintains Target Price $1 - Moomoo
aTyr Pharma (ATYR) Stock Forum and Discussion - Moomoo
JonesTrading Initiates ATyr Pharma(ATYR.US) With Hold Rating - Moomoo
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
TradingKey - TradingKey
aTyr Pharma stock tumbles on new Phase 3 trial plans - Investing.com India
H.C. Wainwright Maintains ATyr Pharma(ATYR.US) With Hold Rating - Moomoo
ATyr Pharma Charts New Path For Efzofitimod In Pulmonary Sarcoidosis; Stock Down - RTTNews
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):